Recombinant Follicle-Stimulating Hormone (Follitropin Beta, Puregon) Yields Higher Pregnancy Rates in In Vitro Fertilization than Urinary Gonadotropins

Slides:

Advertisements

Similar presentations

In Vitro Fertilization

Advertisements

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Antagonists in poor-responder patients

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF Bart C.J.M. Fauser, Michael.

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study Arianna D'Angelo, M.D., Rachel.

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH George Griesinger, Daniel B. Shapiro, Efstratios.

James P Toner, M.D., Ph.D. Fertility and Sterility

Patient-tailored ovarian stimulation for in vitro fertilization

Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation Hermann M. Behre, Colin.

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Day 4 Estradiol Levels Predict Pregnancy Success in Women Undergoing Controlled Ovarian Hyperstimulation for IVF John Y Phelps, M.D., Adam S Levine,

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Ovarian stimulation protocols for IVF: is more better than less?

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.

Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis Cui Hong Zheng, M.D., Ph.D.,

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial Robert Boostanfar, M.D.,

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement Fertility and Sterility Volume 102,

A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.

Mark D Hornstein, M. D. , Owen K Davis, M. D. , Joe B Massey, M. D

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome Uma Deve Gordon, M.D., Robert F Harrison,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH Basil C. Tarlatzis,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran∗). part II. dose-proportionality and gonadotropin suppression after.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Circulating Bioactive and Immunoreactive Recombinant Human Follicle-Stimulating Hormone (Org 32489) After Administration to Gonadotropin-Deficient Subjects

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Withholding gonadotropins (“coasting”) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization–embryo transfer.

Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: Comparison of a new formulation.

Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr Murat Arslan, M.D.,

Fertility and Sterility

Fertility and Sterility

Gonadotropin preparations: past, present, and future perspectives

Luteal phase support Fertility and Sterility

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Fertility and Sterility

Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial Ernesto Bosch, Jon Havelock, Fernando Sánchez.

Performance of basal follicle-stimulating hormone and patient's age in the prediction of poor ovarian response and IVF outcome of women who developed.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

Early pregnancy loss in in vitro fertilization (IVF) is a positive predictor of subsequent IVF success G.Wright Bates, M.D., Elizabeth S Ginsburg, M.D.

Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis Dagmar Rickes,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Hulusi B Zeyneloglu, M.D., Aydin Arici, M.D., David L Olive, M.D.

Ernesto Bosch, M. D. , Elena Labarta, M. D

Presentation transcript:

Recombinant Follicle-Stimulating Hormone (Follitropin Beta, Puregon) Yields Higher Pregnancy Rates in In Vitro Fertilization than Urinary Gonadotropins Henk J Out, Stefan G.A.J Driessen, Bernadette M.J.L Mannaerts, Herjan J.T Coelingh Bennink Fertility and Sterility Volume 69, Issue 2, Pages 40S-44S (February 1998) DOI: 10.1016/S0015-0282(97)00516-5

Fig. 1 Ongoing pregnancy rates (%) after controlled ovarian hyperstimulation, IVF, and fresh ET with recombinant FSH (recFSH) and urinary FSH (uFSH) or hMG as assessed in 25 centers involved in three comparative, randomized clinical trials. Fertility and Sterility 1998 69, 40S-44SDOI: (10.1016/S0015-0282(97)00516-5)